RecruitingNot ApplicableNCT05817929

Angiopoietin and Adverse Outcomes in Cardiac Surgery

Angiopoietin Dysregulation to Predict Adverse Outcomes in Cardiac Surgery: the Prospective


Sponsor

Centre Hospitalier Universitaire, Amiens

Enrollment

200 participants

Start Date

Mar 23, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying blood sample for people with acute kidney injury and cardiac surgery. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood sample

5 ml blood sample will be withdrawn at the surgery start and at the surgery end


Locations(1)

CHU Amiens Picardie

Amiens, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05817929


Related Trials